Sartorius Stedim Biotech 過去の業績
過去 基準チェック /16
Sartorius Stedim Biotechは、平均年間5.4%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間 成長しています。収益は、平均年間13.9% 13.6%収益成長率で 成長しています。 Sartorius Stedim Biotechの自己資本利益率は4.2%であり、純利益率は5.9%です。
主要情報
5.4%
収益成長率
5.3%
EPS成長率
| Life Sciences 業界の成長 | 26.8% |
| 収益成長率 | 13.6% |
| 株主資本利益率 | 4.2% |
| ネット・マージン | 5.9% |
| 次回の業績アップデート | 28 Jan 2025 |
最近の業績更新
Sartorius Stedim Biotech's (EPA:DIM) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 25
Weak Statutory Earnings May Not Tell The Whole Story For Sartorius Stedim Biotech (EPA:DIM)
Feb 19Recent updates
Sartorius Stedim Biotech's (EPA:DIM) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 25Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price Not Quite Adding Up
Oct 15Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Aug 11Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 21Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)
Jul 12Sartorius Stedim Biotech (EPA:DIM) Has A Somewhat Strained Balance Sheet
May 13Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next
Apr 21With A 26% Price Drop For Sartorius Stedim Biotech S.A. (EPA:DIM) You'll Still Get What You Pay For
Apr 20Weak Statutory Earnings May Not Tell The Whole Story For Sartorius Stedim Biotech (EPA:DIM)
Feb 19Sartorius Stedim Biotech S.A.'s (EPA:DIM) Popularity With Investors Is Clear
Dec 22Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?
Dec 01Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?
Nov 10Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Aug 23Sartorius Stedim Biotech (EPA:DIM) Seems To Use Debt Quite Sensibly
May 25Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Is Well Worth Watching
May 09Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?
Apr 23Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly
Feb 07Does Sartorius Stedim Biotech (EPA:DIM) Deserve A Spot On Your Watchlist?
Jan 20Sartorius Stedim Biotech (EPA:DIM) Has A Pretty Healthy Balance Sheet
Nov 09Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Might Deserve Your Attention Today
Oct 20Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)
Oct 03We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt
Jul 26Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?
Jul 09Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value
Jun 21Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt
Apr 21Here's Why I Think Sartorius Stedim Biotech (EPA:DIM) Is An Interesting Stock
Apr 03We Like Sartorius Stedim Biotech's (EPA:DIM) Earnings For More Than Just Statutory Profit
Feb 24収支内訳
収支内訳
Sartorius Stedim Biotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 2,736 | 161 | 641 | 143 |
| 30 Jun 24 | 2,747 | 170 | 636 | 134 |
| 31 Mar 24 | 2,716 | 255 | 625 | 129 |
| 31 Dec 23 | 2,776 | 310 | 618 | 130 |
| 30 Sep 23 | 2,959 | 460 | 598 | 131 |
| 30 Jun 23 | 3,170 | 635 | 619 | 132 |
| 31 Mar 23 | 3,356 | 717 | 604 | 135 |
| 31 Dec 22 | 3,493 | 876 | 612 | 132 |
| 30 Sep 22 | 3,381 | 681 | 605 | 125 |
| 30 Jun 22 | 3,259 | 625 | 577 | 123 |
| 31 Mar 22 | 3,094 | 559 | 564 | 119 |
| 31 Dec 21 | 2,887 | 414 | 532 | 111 |
| 30 Sep 21 | 2,639 | 523 | 479 | 103 |
| 30 Jun 21 | 2,393 | 469 | 450 | 98 |
| 31 Mar 21 | 2,143 | 398 | 417 | 89 |
| 31 Dec 20 | 1,910 | 336 | 392 | 84 |
| 30 Sep 20 | 1,743 | 299 | 373 | 84 |
| 30 Jun 20 | 1,600 | 255 | 353 | 81 |
| 31 Mar 20 | 1,520 | 254 | 334 | 81 |
| 31 Dec 19 | 1,441 | 235 | 318 | 79 |
| 30 Sep 19 | 1,393 | 247 | 308 | 68 |
| 30 Jun 19 | 1,336 | 238 | 301 | 65 |
| 31 Mar 19 | 1,274 | 223 | 293 | 61 |
| 31 Dec 18 | 1,212 | 208 | 283 | 61 |
| 30 Sep 18 | 1,172 | 185 | 277 | 60 |
| 30 Jun 18 | 1,121 | 173 | 264 | 59 |
| 31 Mar 18 | 1,093 | 162 | 259 | 57 |
| 31 Dec 17 | 1,081 | 161 | 258 | 53 |
| 30 Sep 17 | 1,073 | 151 | 252 | 53 |
| 30 Jun 17 | 1,089 | 157 | 255 | 50 |
| 31 Mar 17 | 1,075 | 157 | 250 | 49 |
| 31 Dec 16 | 1,052 | 154 | 244 | 48 |
| 30 Sep 16 | 1,009 | 145 | 242 | 47 |
| 30 Jun 16 | 971 | 142 | 234 | 46 |
| 31 Mar 16 | 926 | 136 | 226 | 43 |
| 31 Dec 15 | 884 | 118 | 217 | 42 |
| 30 Sep 15 | 850 | 111 | 207 | 43 |
| 30 Jun 15 | 781 | 89 | 197 | 35 |
| 31 Mar 15 | 734 | 76 | 189 | 39 |
| 31 Dec 14 | 684 | 72 | 184 | 34 |
| 30 Sep 14 | 646 | 71 | 173 | 39 |
| 30 Jun 14 | 620 | 67 | 168 | 39 |
| 31 Mar 14 | 604 | 68 | 165 | 38 |
| 31 Dec 13 | 588 | 66 | 159 | 36 |
質の高い収益: DIMには€59.6M } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が30th September, 2024に影響を及ぼしています。
利益率の向上: DIMの現在の純利益率 (5.9%)は、昨年(15.6%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: DIMの収益は過去 5 年間で年間5.4%増加しました。
成長の加速: DIMは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。
収益対業界: DIMは過去 1 年間で収益成長率がマイナス ( -65.1% ) となったため、 Life Sciences業界平均 ( 5.4% ) と比較することが困難です。
株主資本利益率
高いROE: DIMの 自己資本利益率 ( 4.2% ) は 低い とみなされます。